omniture
REDCLOUD BIO

Latest News

NEXT-GENERATION EGFR TKI H002 FROM REDCLOUD BIO COMPLETES FIRST DOSE IN NON-SMALL CELL LUNG CANCER

* H002 is a precision therapeutic candidate for the treatment of NSCLC, with broad spectrum and h...

2022-08-29 19:30 2122

REDCLOUD BIO TO PRESENT PRECLINICAL DATA OF NEXT-GENERATION EGFR TKI H002 AT ANNUAL MEETING OF AMERICAN ASSOCIATION OF CANCER RESEARCH

SHANGHAI, April 7, 2022 /PRNewswire/ -- RedCloud Bio (the "Company"), an innovative biotech company...

2022-04-07 19:47 1407

REDCLOUD BIO ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR NEXT-GENERATION EGFR INHIBITOR H002 IN NON-SMALL CELL LUNG CANCER

* Drug Candidate Is First From Company To Enter Phase I/IIa Clinical Trial * H002 Has Potential ...

2022-03-02 17:27 1184